

הודעה על החמרה (מידע בטיחות) בעלון לרופא
(מעודכן 05.2013)

07.05.2013

תאריך:

Avastin® 131.59.31060.00

שם התכשיר באנגלית ומספרי הרישום:

רוש פרמצבטיקה (ישראל) בע"מ

שם בעל הרישום:

טופס זה מיועד לפרוט החמרות בלבד!

החמרות המבוקשות		
טקסט חדש	טקסט נוכחי	פרק בעלון
<p>Necrotising fasciitis, including fatal cases, has rarely been reported in patients treated with Avastin. This condition is usually secondary to wound healing complications, gastrointestinal perforation or fistula formation. Avastin therapy should be discontinued in patients who develop necrotising fasciitis, and appropriate treatment should be promptly initiated.</p>		<p>4.4</p> <p>Special warnings and precautions for use</p>
<p><u>Gastrointestinal perforations (see section 4.4)</u></p> <p>Gastrointestinal perforations have been reported in clinical trials with an incidence of less than 1% in patients with metastatic breast cancer or non-squamous non-small cell lung cancer, up to 2.0% in patients with metastatic renal cell cancer, with relapsed glioblastoma or in patients with ovarian cancer receiving front-line treatment, and up to 2.7% (including gastrointestinal fistula and abscess) in patients with metastatic colorectal cancer.</p>	<p><u>Gastrointestinal perforations (see section 4.4)</u></p> <p>Gastrointestinal perforations have been reported in clinical trials with an incidence of less than 1% in patients with metastatic breast cancer or non-squamous non-small cell lung cancer, and up to 2.0% in patients with metastatic colorectal cancer, with relapsed glioblastoma or with ovarian cancer receiving front-line treatment.</p>	<p>4.8</p> <p>Undesirable effects</p> <p><u>Further information on selected serious adverse reactions</u></p>
<p><u>Fistulae (see section 4.4)</u></p> <p>In clinical trials, gastrointestinal fistulae have been reported with an incidence of up to 2% in patients with metastatic colorectal cancer and ovarian cancer, but were also reported less commonly in patients with other types of cancers.</p>	<p><u>Fistulae (see section 4.4)</u></p> <p>In clinical trials, gastrointestinal fistulae have been reported with an incidence of up to 2% in patients with metastatic colorectal cancer, but were also reported less commonly in patients with other types of cancers.</p>	<p>4.8</p> <p>Undesirable effects</p> <p><u>Further information on selected serious adverse reactions</u></p>

ההחמרות המבוקשות		
טקסט חדש	טקסט נוכחי	פרק בעלון
<p><u>Wound healing (see section 4.4)</u></p> <p>Serious wound healing complications, including anastomotic complications, have been reported, some of which had a fatal outcome.</p>	<p><u>Wound healing (see section 4.4)</u></p>	<p>4.8</p> <p>Undesirable effects</p> <p><u>Further information on selected serious adverse reactions</u></p>
<p><u>Posterior Reversible Encephalopathy Syndrome (see section 4.4)</u></p> <p>There have been rare reports of Avastin-treated patients developing signs and symptoms that are consistent with PRES, a rare neurological disorder. Presentation may include seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. The clinical presentation of PRES is often nonspecific, and therefore the diagnosis of PRES requires confirmation by brain imaging, preferably MRI.</p> <p>In patients developing PRES, early recognition of symptoms with prompt treatment of specific symptoms including control of hypertension (if associated with severe uncontrolled hypertension) is recommended in addition to discontinuation of bevacizumab therapy. Symptoms usually resolve or improve within days after treatment discontinuation, although some patients have experienced some neurologic sequelae. The safety of reinitiating Avastin therapy in patients previously experiencing PRES is not known.</p> <p>Across clinical trials, 8 cases of PRES have been reported. Two of the eight cases did not have radiological confirmation via MRI.</p>		<p>4.8</p> <p>Undesirable effects</p> <p><u>Further information on selected serious adverse reactions</u></p>

ההחמרות המבוקשות		
טקסט חדש	טקסט נוכחי	פרק בעלון
<p><u>Proteinuria (see section 4.4)</u></p> <p>Grade 3 proteinuria was reported in up to 8.1% of treated patients.</p>	<p><u>Proteinuria (see section 4.4)</u></p> <p>Grade 3 proteinuria was reported in < 3% of treated patients; however, in patients treated for advanced and/or metastatic renal cell carcinoma this was up to 7% in patients having minimal to no proteinuria at baseline.</p>	<p>4.8</p> <p>Undesirable effects</p> <p><u>Further information on selected serious adverse reactions</u></p>
<p><u>Haemorrhage (see section 4.4)</u></p> <p>In clinical trials across all indications the overall incidence of NCI-CTCAE v.3 Grade 3-5 bleeding reactions ranged from 0.4% to 6.5% in Avastin treated patients, compared with up to 2.9% of patients in the chemotherapy control group.</p>	<p><u>Haemorrhage (see section 4.4)</u></p> <p>In clinical trials across all indications the overall incidence of NCI-CTC Grade 3-5 bleeding events ranged from 0.4% to 5% in Avastin treated patients, compared with up to 2.9% of patients in the chemotherapy control group.</p>	<p>4.8</p> <p>Undesirable effects</p> <p><u>Further information on selected serious adverse reactions</u></p>
<p><u>Elderly patients</u></p> <p>In one clinical trial, the incidence of hypertension of grade ≥ 3 was twofold higher in patients aged > 65 years than in the younger age group (<65 years).</p>	<p><u>Elderly patients</u></p>	<p>4.8</p> <p>Undesirable effects</p> <p><u>Further information on selected serious adverse reactions</u></p>
<p><u>Table 2: Adverse reactions reported in post-marketing setting</u></p> <p>System organ class (SOC): Infections and Infestations</p> <p>Reactions (frequency*): Necrotising fasciitis, usually secondary to wound healing complications, gastrointestinal perforation or fistula formation (rare) (see also section 4.4)</p>	<p><u>Table 2: Adverse reactions reported in post-marketing setting</u></p>	<p>4.8</p> <p>Undesirable effects</p> <p><u>Post-marketing experience</u></p>

מצ"ב העלון, שבו מסומנות ההחמרות המבוקשות על רקע צהוב. שינויים שאינם בגדר החמרה סומנו (בעלון) בטקסט בצבע.

הועבר בדואר אלקטרוני בתאריך: 07.05.2013.